Unibest
← Back to patent-cliff list

Abivertinib

Tier C — Watch / trade

Abivertinib

-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:BTK, EGFR T790M

Indications (approved):Non-small cell lung cancer, Non-Hodgkin lymphoma, Lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma, Mantle cell lymphoma, Prostate cancer, COVID-19

Regional status

US
Discontinued
2020-10-09
EU
Discontinued
2015-05-01
China
Phase III
2018-12-01
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 7 · Total yield /
AVITI-00190213-66-4AVITI-002442847-52-1AVITI-003554-84-7AVITI-0041557268-35-5AVITI-005221198-99-8AVITI-0061557268-58-2AVITI-0071557268-61-7AVITI-008814-68-6AVITI-0091557268-64-0AVITI-0101557267-50-1API · Abivertinib
CodeCAS No.Intermediate
AVITI-00190213-66-4Available2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine
AVITI-002442847-52-12,4-dichloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine
AVITI-003554-84-73-nitrophenol
AVITI-0041557268-35-52-chloro-4-(3-nitrophenoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine
AVITI-005221198-99-83-fluoro-4-(4-methylpiperazin-1-yl)aniline
AVITI-0061557268-58-2N-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-(3-nitrophenoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
AVITI-0071557268-61-74-(3-aminophenoxy)-N-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
AVITI-008814-68-6Availableacryloyl chloride
AVITI-0091557268-64-0N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide
AVITI-0101557267-50-1N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-(hydroxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide

Frequently asked questions

What are the approved indications of Abivertinib?

Approved indications include: Non-small cell lung cancer, Non-Hodgkin lymphoma, Lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma, Mantle cell lymphoma, Prostate cancer, COVID-19.

When does the Abivertinib patent expire?

No public expiry year is available for Abivertinib yet; this page updates once verified.

How many synthesis routes are recorded for Abivertinib?

1 synthesis routes are recorded; the shortest is 7 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Abivertinib intermediates?

2 intermediate CAS of Abivertinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Abivertinib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-08